WithdrawnEarly phase 1
Adherence to Otezla
Reason given: Terminated IRB approval 6/26/2024, study was never initiated or activated
Key facts
- Where
- Winston-Salem, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesNo longer taking part
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT05601492
- Record updated
- 29 May 2025
- Original description
Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.Read full original descriptionShow less
Adherence to Otezla in Patients With Mild Psoriasis
Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.
Inclusion: Adult 18 years or older; Diagnosis of mild psoriasis with Otezla recommendation; Non-pregnant; English speaking.
Exclusion: Under 18 years of age; Not diagnosis of mild psoriasis; Pregnant; Non-English speaking.